AGTC Names Matthew Feinsod Product Development Officer - Quick Facts

(RTTNews) - Applied Genetic Technologies Corp. (AGTC), a clinical stage biotechnology company developing adeno-associated virus -based gene therapies for the treatment of rare eye diseases, Tuesday announced the appointment of Matthew Feinsod to the position of Product Development Officer.

Feinsod is a board-certified ophthalmologist with extensive corporate and regulatory expertise in the development of novel therapies for ophthalmic diseases.

He has been a founder in several companies and holds multiple patents in the field of ophthalmology.

The company noted that Feinsod expects to continue his active practice in ophthalmology during his employment by AGTC.

Most recently, Feinsod was founder and Chief Medical Officer of Imagen Biotech, a venture-backed company dedicated to developing breakthrough ophthalmology treatments. Prior to Imagen, he was SVP of Strategy and Product Development at Eyetech Pharmaceuticals.

He has also served as medical officer for the U.S. Food & Drug Administration or FDA, Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products.

Sue Washer, President and Chief Executive Officer of AGTC, said, "As a practicing ophthalmologist and serial entrepreneur, Matt brings a unique perspective to the development of novel therapies for eye diseases with unmet needs. He has a deep appreciation for how these diseases impact patients and a track record of success in innovating new ways to treat those diseases."